ArticlePediatric blood & cancer2018

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).

Eric S Schafer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.